A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Type 2 Diabetes
About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria: Have Type 2 Diabetes Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol) despite diet and exercise treatment Are of stable weight 5%) during the 90 days preceding screening and agree not to initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment Have Body Mass Index (BMI) ≥23.0 kilogram per square meter (kg/m²) Exclusion Criteria: Have Type 1 Diabetes Have a history of chronic or acute pancreatitis any time prior to study entry Are currently receiving treatment for diabetic retinopathy and/or macular edema Have a history of ketoacidosis or hyperosmolar state/coma Have a history of New York Heart Association Functional Classification IV congestive heart failure (CHF) Have acute or chronic hepatitis including a history of autoimmune hepatitis Use of insulin 1-year preceding screening and between screening and baseline; use of any antihyperglycemic medication 90 days preceding screening and between screening and baseline.
Sites / Locations
- Chinese PLA General HospitalRecruiting
- Shunde Hospital of Southern Medical UnivesityRecruiting
- Huizhou Municipal Central HospitalRecruiting
- Zunyi First People's HospitalRecruiting
- Hainan General Hospital
- The Fourth Hospital of Harbin Medical UniversityRecruiting
- The First Affiliated Hospital of Henan University of Science &TechnologyRecruiting
- The First Affiliated Hospital of Nanyang Medical CollegeRecruiting
- The Second Affiliated Hospital of Zhengzhou UniversityRecruiting
- Yichang Central People's HospitalRecruiting
- The First People's Hospital of Changde City
- Changzhou No.2 People's HospitalRecruiting
- Nanjing First HospitalRecruiting
- The Second Affiliated Hospital of Nanjing Medical UniversityRecruiting
- Nanjing Medical University - Nanjing Jiangning HospitalRecruiting
- The First Affiliated Hospital of Soochow UniversityRecruiting
- Affiliated Hospital of Jiangsu UniversityRecruiting
- Jiangxi Pingxiang People's HospitalRecruiting
- Dalian University - The Affiliated Zhongshan HospitalRecruiting
- Dalian Municipal Central Hospital Affiliated of Dalian Medical UniversityRecruiting
- Panjin Liaoyou Baoshihua Hospital
- The First Affiliated Hospital of Xi'an Medical UniversityRecruiting
- Jinan Central HospitalRecruiting
- Pudong New Area People's Hospital ShanghaiRecruiting
- Jiading District Central HospitalRecruiting
- West China Hospital of Sichuan UniversityRecruiting
- Chengdu Fifth People's HospitalRecruiting
- Tianjin Medical University General HospitalRecruiting
- Huzhou Central HospitalRecruiting
- Ningbo First Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
Tirzepatide Dose 1
Tirzepatide Dose 2
Tirzepatide Dose 3
Placebo
Participants will receive tirzepatide subcutaneously (SC).
Participants will receive tirzepatide SC.
Participants will receive tirzepatide SC.
Participants will receive placebo.